Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. 1983

E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo

Kinetic analyses of insulin metabolism were performed in 32 healthy subjects with hepatic-venous or renal-venous catheters, in whom steady-state conditions of hyperinsulinemia or hyperglycemia were achieved with the use of the glucose-insulin clamp technique. In the basal state, the splanchnic bed removed 42 +/- 2% of the insulin influx. After graded insulin infusions with maintenance of euglycemia, stable arterial insulin levels of 35-1,430 microU/ml were attained. Splanchnic insulin extraction was constant (approximately 60%) at physiological insulin levels but fell (to 29 +/- 1%, P less than 0.02) at supraphysiological (greater than 500 microU/ml) concentrations. The metabolic clearance rate of infused insulin was essentially constant within the physiological concentration range. Hyperglycemia (+125 mg/100 ml) did not alter splanchnic insulin extraction. Basally, the kidneys extracted 0.04 +/- 0.01 mU X min-1 X kg-1 or 25 +/- 5% of arterial insulin. Renal insulin clearance (3.9 +/- 0.4 ml X min-1 X kg-1) represented over 80% of the extrasplanchnic insulin clearance. Hyperglycemia (+125 mg/100 ml) had no effect on renal insulin extraction. In conclusion, a) both splanchnic and renal insulin removal are independent of glycemia and increase in proportion to plasma insulin concentration within the physiological range; b) splanchnic uptake is the dominant mechanism of removal of insulin from the circulation whether the route of delivery is portal or peripheral; and c) the kidneys account for the greater part of extrasplanchnic insulin metabolism.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008102 Liver Circulation The circulation of BLOOD through the LIVER. Hepatic Circulation,Circulation, Liver,Circulation, Hepatic
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
January 1988, Acta endocrinologica,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
November 1983, The American journal of physiology,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
May 1973, European journal of clinical investigation,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
January 1991, Acta diabetologica,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
June 2005, Diabetes care,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
March 1993, Annals of the New York Academy of Sciences,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
February 1956, The Journal of clinical investigation,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
January 1991, Clinical science (London, England : 1979),
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
March 2020, NPJ biofilms and microbiomes,
E Ferrannini, and J Wahren, and O K Faber, and P Felig, and C Binder, and R A DeFronzo
January 2017, Amino acids,
Copied contents to your clipboard!